Table 2 Clinicopathological characteristics and outcome of men with pN+ classified for different anatomical regions
From: Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for prostate Cancer
External | Internal | Obturator | Ext. + Int. | Ext. + Obt. | Int. + Obt. | Ext. + Int. + Obt. | |
|---|---|---|---|---|---|---|---|
Patients (n) | 23 | 14 | 21 | 6 | 8 | 10 | 12 |
Baseline | |||||||
PSA (median (IQR)) (ng/ml) | 18 (9–36) | 16 (11–32) | 12 (6–26) | 19.7 (15–45) | 7.3 (4–39) | 56.9 (14–91) | 21.8 (20–40) |
Histopathology (prostatectomy) | |||||||
GS 6 | – | – | – | – | – | – | – |
GS 7a | 2 (9%) | 1 (7%) | 6 (29%) | – | – | 2 (20%) | 1 (8%) |
GS 7b | 2 (9%) | 6 (43%) | 7 (33%) | 2 (33%) | 2 (25%) | – | 1 (8%) |
GS 8 | 9 (39%) | 2 (14%) | 1 (5%) | 3 (50%) | 3 (38%) | 3 (30%) | 4 (33%) |
GS 9–10 | 10 (43%) | 5 (36%) | 6 (29%) | – | 3 (38%) | 5 (50%) | 4 (33%) |
Unknown | – | – | 1 (5%) | 1 (17%) | – | – | 2 (17%) |
pT Stage | |||||||
pT2 (n) | 4 (17%) | – | 2 (10%) | – | 2 (25%) | – | 1 (8%) |
pT3a (n) | 11 (48%) | 10 (71%) | 10 (48%) | 1 (17%) | 3 (38%) | 3 (30%) | 2 (17%) |
pT3ba (n) | 8 (35%) | 4 (29%) | 8 (38%) | 4 (67%) | 3 (38%) | 7 (70%) | 7 (58%) |
Unknown | – | – | 1 (5%) | 1 (17%) | – | – | 2 (17%) |
Lymph node dissection | |||||||
Number of resected LN (mean (±STD)) | 20 (±7.2) | 20.4 (±7.3) | 19.7 (±6.7) | 23.7 (±12.8) | 19.8 (±6.3) | 24.1 (±11.3) | 21.4 (±6.2) |
Number of positive LN (mean (±STD)) | 1.4 (±0.7) | 1.1 (±0.3) | 1.5 (±0.7) | 3.7 (±1.4) | 3 (±1.2) | 3.5 (±1.8) | 7.3 (±3.2) |
Ratio positive LN/all LN (%) | 8.3 | 4.6 | 8.7 | 17.1 | 15.7 | 18.4 | 37.0 |
Follow-Up | |||||||
PSA persistence (%) | 50 | 20.8 | 42.9 | 50 | 50 | 70 | 91.7 |
1y BCRFS (%) | 71.1 | 80 | 65.6 | 100 | 50 | 66.7 | 100b |